Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 19/20 | 0.80 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.74 |
| ▸ | KIT | P10721 | 1/20 | 0.74 |
| ▸ | FLT1 | P17948 | 1/20 | 0.74 |
| ▸ | FLT4 | P35916 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529379 | 0.89 | RXFP1 (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL5964880 | 0.87 | RXFP1 (0.61) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL15528722 | 0.87 | RXFP1 (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL29356168 | 0.85 | KDR (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL4976103 | 0.85 | KDR (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL3110637 | 0.84 | KDR (0.66) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL1037818 | 0.80 | RXFP1 (0.75) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL4978213 | 0.80 | KDR (0.79) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL2489551 | 0.80 | ABL1 (0.78) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL1011471 | 0.80 | RXFP1 (0.80) | RXFP1ABL1EGFRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2676953-B1 | HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3 -TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID FOR USE IN THE TREATMENT OF LYMPHOCYTE MEDIATED DISEASES | NOVARTIS AG (CH) | 2017-03-22 | — | — | EP | claimed |
| EP-1633336-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2016-06-22 | — | — | EP | claimed |
| EP-2676953-A1 | Hemifumarate Salt and Medical Indications | Novartis AG (CH) | 2013-12-25 | — | — | EP | claimed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | claimed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | claimed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | claimed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | claimed |
| US-20240239743-A1 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20230357142-A9 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | NOVARTIS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20220402870-A1 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| EP-2959894-B1 | S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | NOVARTIS AG (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-20210323915-A1 | HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| EP-3797765-A1 | S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| WO-2004071442-A2 | NOVEL BICYCLIC COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-08-26 | — | — | WO | disclosed |
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | IRM LLC (BM) | 2004-03-11 | — | — | US | disclosed |
| WO-2003099192-A2 | BIS-AROMATIC ALKANOLS | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003097028-A1 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323915-A1 | HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID | QDPR, CYP4F11, CYP2F1 | RXFP1 3377/4885ABL1 536/4885EGFR 1708/4885 |
| US-20220402870-A1 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | ETV1, ENY2, SLC10A1 | RXFP1 2389/4885ABL1 428/4885EGFR 540/4885 |
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | CD4, HLA-DRB1, MALT1 | RXFP1 4794/4885ABL1 656/4885EGFR 3400/4885 |
| US-20240239743-A1 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | ETV1, QDPR, SLC10A1 | RXFP1 2620/4885ABL1 410/4885EGFR 550/4885 |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | RXFP1 106/4885ABL1 171/4885EGFR 8/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | RXFP1 87/4885ABL1 152/4885EGFR 7/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | RXFP1 128/4885ABL1 167/4885EGFR 8/4885 |
| US-20230357142-A9 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | ETV1, ENY2, SLC10A1 | RXFP1 2389/4885ABL1 428/4885EGFR 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.